Banco Santander S.A. increased its stake in Mylan N.V. (NASDAQ:MYL) by 29.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,604 shares of the company’s stock after buying an additional 3,738 shares during the period. Banco Santander S.A.’s holdings in Mylan N.V. were worth $566,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Personal Financial Services raised its position in Mylan N.V. by 33.2% in the first quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock valued at $107,000 after buying an additional 681 shares during the period. Global X Management Co. LLC raised its position in Mylan N.V. by 91.6% in the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after buying an additional 1,441 shares during the period. Ropes Wealth Advisors LLC acquired a new position in Mylan N.V. during the first quarter valued at approximately $136,000. Oakworth Capital Inc. raised its position in Mylan N.V. by 30.7% in the first quarter. Oakworth Capital Inc. now owns 4,255 shares of the company’s stock valued at $166,000 after buying an additional 1,000 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in Mylan N.V. during the first quarter valued at approximately $188,000. 69.89% of the stock is owned by institutional investors.
Mylan N.V. (NASDAQ MYL) traded up 0.91% during mid-day trading on Tuesday, hitting $37.57. 1,781,791 shares of the company’s stock were exchanged. The stock has a market capitalization of $20.14 billion, a P/E ratio of 37.53 and a beta of 1.23. Mylan N.V. has a 52 week low of $33.60 and a 52 week high of $50.40. The firm has a 50 day moving average of $38.54 and a 200 day moving average of $39.04.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.01. Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter in the prior year, the firm earned $0.76 EPS. The company’s revenue was up 24.1% on a year-over-year basis. Equities analysts forecast that Mylan N.V. will post $5.19 earnings per share for the current fiscal year.
Several research analysts have recently commented on the stock. Zacks Investment Research raised shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Tuesday. BidaskClub raised shares of Mylan N.V. from a “strong sell” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald assumed coverage on shares of Mylan N.V. in a report on Friday. They issued a “neutral” rating and a $41.00 price target for the company. ValuEngine lowered shares of Mylan N.V. from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $41.00 price target on shares of Mylan N.V. in a report on Tuesday, June 13th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $50.77.
In other Mylan N.V. news, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider now directly owns 140,653 shares in the company, valued at approximately $5,626,120. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Laboratories Abbott sold 44,000,000 shares of the company’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total transaction of $1,830,400,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,035,000 shares of company stock worth $1,831,800,000. Insiders own 0.69% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.